Reports Q4 revenue $1.16B, consensus $1.11B. “The Illumina (ILMN) team delivered a strong finish to 2025, marking a return to growth through disciplined execution against our strategy,” said Jacob Thaysen, Chief Executive Officer of Illumina. “Momentum built in the second half of the year – especially in clinical markets, where adoption of NGS-based testing is expanding – reinforces our confidence as we enter 2026.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Notable companies reporting after market close
- These Are the Stocks Reporting Earnings Today – February 5, 2026
- Illumina partners with San Diego Zoo Wildlife Alliance for genetics conservation
- ILMN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Illumina Completes SomaLogic Acquisition, Expands Proteomics Capabilities